Covid19 – Novavax begins vaccine trials on youngsters
US biotech agency Novavax stated Monday it had began scientific trials of its proposed Covid-19 vaccine on youngsters, in a program that may contain as much as 3,000 adolescents aged 12-17. Contributors can be monitored for as much as two years after their injections.
Learn additionally – FDA to authorise Pfizer vaccines for adolescents
Far fewer youngsters have been sick with Covid-19 in comparison with adults, and most have gentle to no signs, however they are often contaminated and unfold the virus.
The Novavax vaccine, which makes use of totally different know-how from the doses already broadly licensed all over the world, is a protein-based vaccine engineered from the genetic sequence of the primary pressure of the coronavirus.
The Novavax vaccine has not but been approved in any nation, together with for adults, however the firm plans to file for emergency authorization in Britain “within the second quarter of 2021”, adopted by in america.
Different vaccine firms together with Moderna, Johnson & Johnson and Pfizer are additionally conducting trials in adolescents.